Abstract：Objective： To investigate the efficacy of transurethral holmium laser resection of bladder tumor （HoLRBT） in the treatment of non-muscular invasive bladder cancer （NMIBC） and its effect on tumor factors. Methods： The clinical data of 134 patients with NMIBC were retrospectively analyzed. Patients treated with HoLRBT were enrolled as HoLRBT group （n=68） and those treated with transurethral resection of bladder tumor （TURBT） were enrolled as TURBT group （n=66）. Surgical data, complications and postoperative recurrence were compared between the two groups. The serum carcinoembryonic antigen （CEA） and thymidine kinase 1 （TK1） and urinary nuclear matrix protein 22 （NMP22） levels were determined in two groups before and after surgery. Results： The operation time, catheter indwelling time and hospital stay in HoLRBT group were significantly shorter than those in TURBT group, and the hospitalization cost in HoLRBT group was significantly greater than that in TURBT group （P < 0.05）. The incidences of bladder perforation and obturator nerve reflex in HoLRBT group were significantly lower than those in TURBT group （P < 0.05）. The recurrent rate in HoLRBT group at 6th month, 1st year and 3rd year after surgery was significantly lower than that in TURBT group （P < 0.05）. One month after surgery, serum CEA, TK1 and NMP22 levels in two groups were significantly reduced, and those in HoLRBT group were significantly lower than those in TURBT group （P < 0.05）. Conclusion： Compared with TURBT, HoLRBT has a significant effect in the treatment of NMIBC, which can effectively reduce surgical complications and postoperative recurrent rate.
[1] CUMBERBATCH MGK, FOERSTER B, CATTO JWF, et al.Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol, 2018,73(6):925-933. [2] 冯权尧,徐勋,赵振华,等.经尿道钬激光切除术与等离子电切术治疗非肌层浸润性膀胱癌的疗效分析.现代泌尿生殖肿瘤杂志,2019,11(1):24-27,42. [3] BABJUK M, BÖHLE A, BURGER M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol, 2017,71(3):447-461. [4] 李亚伟,程浪,黄后宝.经尿道膀胱肿瘤海博刀整块切除与经尿道膀胱肿瘤电切治疗非肌层浸润性膀胱癌的疗效及安全性对比分析.现代泌尿生殖肿瘤杂志,2019,11(4):209-215. [5] 刘定益,胡桑,王健,等.钬激光与等离子电切治疗浅表性膀胱尿路上皮癌的疗效比较.现代肿瘤医学,2018,26(3):412-415. [6] SPIESS PE, AGARWAL N, BANGS R, et al.Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2017,15(10):1240-1267. [7] 田官强,程量,周志豪,等.经尿道激光与电切术治疗非肌层浸润性膀胱癌效果及安全性比较的Meta分析.第三军医大学学报,2019,41(14):1387-1396. [8] 宋伟,杨科,高智勇,等.经尿道电切术与经尿道双极等离子电切术治疗非肌层浸润性膀胱肿瘤的疗效比较研究.现代生物医学进展,2017,17(18):3490-3493. [9] 雷超,廖凯,董文瑞.经尿道钬激光膀胱肿瘤切除术与电切术对非肌层浸润性膀胱癌的疗效对比.实用癌症杂志,2019,34(2):296-299. [10] 罗勇,唐飞,冀荣俊,等.经尿道前列腺等离子电切术与传统电切术对前列腺增生患者性功能的影响.中国性科学,2019,28(2):21-23. [11] 叶金汉,陈艺林,李坤,等.经尿道铥激光整块切除与等离子电切治疗膀胱肿瘤的疗效对比分析.微创泌尿外科杂志,2019,8(3):168-172. [12] 曹敬毅,王淇超,孙卫兵,等.钬激光技术治疗非肌层浸润性膀胱癌的临床疗效分析.国际泌尿系统杂志,2018,38(2):185-187. [13] 费安华,付明,胡刚强,等.经尿道膀胱肿瘤电切术治疗高级别非肌层浸润性膀胱癌的疗效分析.癌症进展,2019,17(15):1839-1842. [14] SORIA F, MARRA G, D'ANDREA D, et al. The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer. Transl Androl Urol, 2019,8(1):46-53. [15] JIANG ZF, WANG M, XU JL.Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. Life Sci, 2018,194(2):1-6. [16] JAGARLAMUDI KK, SHAW M.Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker. Biomark Med, 2018,12(9):1035-1048. [17] 吕天兵. 核基质蛋白22、细胞角质素20和存活素mRNA对膀胱癌诊断价值的研究.国际检验医学杂志,2017,38(18):2551-2553. [18] 马进华,魏红兵,李先林,等.经尿道钬激光切除术对非肌层浸润性膀胱癌患者氧化应激因子和肿瘤相关因子的影响.新疆医科大学学报,2020,43(2):158-162.
